In subgroup analyses , all cause mortality was significantly lower in trials with vitamin D3 supplementation than in trials with vitamin D2 supplementation ( P for interaction=0.04 ) ; neither vitamin D3 nor vitamin D2 was associated with a statistically significant reduction in all cause mortality .
CONCLUSIONS Vitamin D supplementation alone was not associated with  all cause mortality in adults compared with placebo or no treatment .
Vitamin D supplementation reduced the risk of cancer death by 16 % .
Additional large clinical studies are needed to determine whether vitamin D3 supplementation is associated with lower all cause mortality .
OBJECTIVE To investigate whether vitamin D supplementation is associated with lower mortality in adults .
The effect of vitamin D supplementation on knee osteoarthritis, the VIDEO study: a randomised controlled trial.
OBJECTIVE Epidemiological data suggest low serum 25-hydroxyvitamin D3 ( 25-OH-D3 ) levels are associated with radiological progression of knee osteoarthritis ( OA ) . This study aim ed to assess whether vitamin D supplementation can slow the rate of progression . METHOD A 3-year , double-blind , r and omised , placebo-controlled trial of 474 patients aged over 50 with radiographically evident knee OA comparing  800 IU cholecalciferol daily with placebo . Primary outcome was difference in rate of medial joint space narrowing ( JSN ) . Secondary outcomes included lateral JSN , Kellgren & Lawrence grade , Western Ontario and McMaster Universities Osteoarthritis Index ( WOMAC ) pain , function , stiffness and the Get up and Go test . RESULTS Vitamin D supplementation  increased 25-OH-D3 from an average of 20.7 ( st and ard deviation ( SD ) 8.9 ) μg/L to 30.4 ( SD 7.7 ) μg/L , compared to 20.7 ( SD 8.1 ) μg/L and 20.3 ( SD 8.1 ) μg/L in the placebo group . There was no significant difference in the rate of JSN over 3 years in the medial compartment of the index knee between the treatment group ( average -0.01 mm/year ) and placebo group ( -0.08 mm/year ) , average difference 0.08 mm/year ( 95 % confidence interval ( CI ) [ -0.14 - 0.29 ] , P = 0.49 ) . No significant interaction was found between baseline vitamin D levels and treatment effect . There were no significant differences for any of the secondary outcome measures . CONCLUSION Vitamin D supplementation did not slow the rate of JSN or lead to reduced pain , stiffness or functional loss over a 3-year period . On the basis of these findings we consider that vitamin D supplementation has no role in the management of knee OA
In subgroup analyses , all cause mortality was significantly lower in trials with vitamin D3 supplementation than in trials with vitamin D2 supplementation ( P for interaction=0.04 ) ; neither vitamin D3 nor vitamin D2 was associated with a statistically significant reduction in all cause mortality .
CONCLUSIONS Vitamin D supplementation alone was not associated with  all cause mortality in adults compared with placebo or no treatment .
Vitamin D supplementation reduced the risk of cancer death by 16 % .
Additional large clinical studies are needed to determine whether vitamin D3 supplementation is associated with lower all cause mortality .
OBJECTIVE To investigate whether vitamin D supplementation is associated with lower mortality in adults .